FFB 2 8 2006

PTC/SB/08a(08/03)

Approved for use through 07/31/2008, OMB 0651-0031

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Pagerwork Reduction Act of 1895, no persons are required to respond to a collection of information unless it disables a valid. OMB control number

Sesentile for form 1449A/PTO				Application Number	10/520,771		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Filing Date	December 5, 2005		
				First Named Inventor	Mohammad Reza MEHRABI		
				Art Unit	1615		
				Examiner Name			
Sheet	1	of	2	Attorney Docket No.	TOMK0004		

Evenines	Cite	Document No.	U.S. PATENT		ame of Patentee or	Baces C	olumne Lines Mhom	Dolovica	
Examiner Cite Initials No.1		Document No. No. – Kind Code ²			plicant of Cited Doc	Passag	Pages, Columns, Lines, Where Relevar Passages or Relevant Figures Appear		
	!								
			_			-			
			-			· · · ·			
		· · · · · · · · · · · · · · · · · · ·				-			
							· · · · · · · · · · · · · · · · · · ·		
	<u> </u>	FC	DREIGN PATE	NT DOC	UMENTS				
	I I	Foreign Patent Documer	nt Pu	Publication Name of Pa		or Applicant	Pages, Columns. Lines Where	·	
Examiner Initials	Cite No.1	Country Code ³ Number ⁴ Kind Co	ode ⁵ MM-	Date DD-YYYY	of Cited De	oc	Lines Where Relevant Passages or Relevant Figures Appear	`τ*	
					•				
					·				
		· · · · · · · · · · · · · · · · · · ·							
				·	·				
	\sqcup				DA				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08a(08/03)
Approved for use through 07/31/2006, OMB 0551-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO				Application Number	10/520,771
				Filing Date	December 5, 2005
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	Mohammad Reza MEHRABI
				Art Unit	1615
				Examiner Name	
Sheet	2	of	2	Attorney Docket No.	TOMK0004

		NON PATENT LITERATURE DOCUMENTS					
Examiner Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published					
		International Search Report, Application No. POT/AT 09/09252 no pub date					
/T.P.T./		DIAZ-FLORES, ET AL., "Intense Vascular Sprouting From Rat Femoral Vein Induced by Prostaglandins E1 and E2"; The Anatomical Record; January 1994; pp. 68-76; Vol. 238; Wiley-Liss, Inc.	•				
		KÖPF-MAIER, ET AL., "Influence of dispase and angiogenesis factors on the growth of human xenografts"; Journal of Cancer Research and Clinical Oncology; 1988; pp. 547-552; Vol. 114.					
		GULLINO, "PROSTAGLANDINS AND GANGLIOSIDES OF TUMOR MICROENVIRONMENT: THEIR ROLE IN ANGIOGENESIS"; Acta Oncologica; 1995; pp. 439-441; Vol. 34, No. 3; Scandinavian University Press.					
		COHEN, MD., "Erythromelalgia: New theories and new therapies"; Journal of American Academy of Dermatology; 2000; pp. 841-847.					
			<u> </u>				
			ļ				
	_						
<u>-</u>			<u> </u>				
			I				

EXAMINER SIGNATURE	/Timothy Thomas/	DATE CONSIDERED	02/05/2008
	Translating Translatin	 CONGIDENCE	· ·

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.